Background It is widely acknowledged that HPV prophylactic vaccine could prevent new infections and their associated lesions among women who were predominantly HPV-naïve at vaccination. Yet there still remains uncertainty about whether HPV vaccination benefits to individuals who had undergone surgery for cervical disease. Methods This post-hoc analysis intends to focus on intent-to-treat participants who underwent excision treatment at baseline and the follow-up period in a phase II/III, double-blind, randomized trial (ClinicalTrials.gov, number NCT00779766) conducted in Jiangsu province, China. We evaluate the impact of HPV vaccination on preventing subsequent infection and cervical lesions (LSIL + and CIN2+) after excision treatment. Results 168 (vaccine, n = 87; control, n = 81) performed excisional treatment in this clinical trial. We observed a significant effect of vaccination on rates of 14 types oncogenic HPV infection after treatment (vaccine efficacy: 27.0%; 95% CI 4.9%, 44.0%). Vaccine efficacy estimates against new infections after treatment for 14 types oncogenic HPV infection were 32.0% (95%CI 1.8%, 52.8%), for HPV16/18 infection were 41.2% (95%CI -162.7%, 86.8%).The accumulative clearance rate of the vaccine group and placebo group were respectively 88.9%, 81.6% for HPV16/18 infection (P = 0.345), 63.4%, 48.7% for 14 types oncogenic HPV infection (P = 0.062). There was no significant difference for the persistent rate of HPV16/18, 14 types oncogenic HPV infection and occurrence rate of LSIL + between the two groups. Conclusions There is no evidence that HPV-16/18 AS04-adjuvanted vaccine could lead to viral faster clearance or had effect on the persistent infection rate of the women after excision treatment. The women after treatment may get beneficial from the “primary prophylactic” effect of vaccine, while prophylactic HPV vaccine’ use as therapeutic agents deserves further researched.

Background: It is widely acknowledged that HPV prophylactic vaccine could prevent new infections and their associated lesions among women who were predominantly HPV-naive at vaccination. Yet there still remains uncertainty about whether HPV vaccination could benefit to individuals who had undergone surgery for cervical disease. Methods: This post-hoc analysis intends to focus on intent-to-treat participants who underwent excision treatment at baseline and the follow-up period in a phase II/III, double-blind, randomized trial (ClinicalTrials.gov, number NCT00779766) conducted in Jiangsu province, China. We evaluate the impact of HPV vaccination on preventing women from subsequent infection and cervical lesions (LSIL+ and CIN2+) after excision treatment. Results: 168 (vaccine, n=87; placebo, n=81) performed excisional treatment in this clinical trial. We observed a significant effect of vaccination on acquiring 14 high-risk HPV (HR-HPV) infection after treatment (vaccine efficacy: 27.0%; 95% CI 4.9%, 44.0%). The vaccine efficacy against new infections after treatment for 14 HR-HPV infection was estimated as 32.0% (95%CI 1.8%, 52.8%), and was 41.2% (95%CI -162.7%, 86.8%) for HPV16/18 infection. The accumulative clearance rates of the vaccine group and placebo group were 88.9% and 81.6% for HPV16/18 infection (P=0.345), 63.4%, 48.7% for 14 HR-HPV infection (P=0.062), respectively. No significant difference was observed on the persistent rate of HPV16/18, 14 HR-HPV infection and occurrence rate of LSIL+ between the two groups. Conclusions: No significant evidence from this study showed that HPV-16/18 AS04-adjuvanted vaccine could lead to viral faster clearance or have any effect on the rates of persistent infection among women who had excision treatment. However, the vaccine may still benefit post-treatment women with “primary prophylactic” effect. Further research is required in clarifying the effect of using the prophylactic HPV vaccine as therapeutic agents. ClinicalTrials.gov Identifier: NCT00779766Date and status of trial registration: October 24, 2008 Completed; Has Results